Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Henlius (02696.HK) HLX07 Combined with HANSIZHUANG Clinical Trial Approved to Commence in Australia
Recommend 1 Positive 1 Negative 0 |
||||
|
||||
|
Henlius (02696.HK) announced that a Phase 2/3 clinical trial of its self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) in combination with HANSIZHUANG (serplulimab injection) and chemotherapy, compared with placebo plus HANSIZHUANG or pembrolizumab and chemotherapy, as first-line treatment for advanced squamous non-small cell lung cancer, has been approved by the relevant Human Research Ethics Committee and has completed clinical trial notification filing with the Therapeutic Goods Administration of Australia. (de/d) Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
